Home » EMA Recommends Roche’s RoActemra for Adults with Severe COVID-19
EMA Recommends Roche’s RoActemra for Adults with Severe COVID-19
The European Medicines Agency (EMA) has endorsed Roche’s arthritis therapy RoActemra (tocilizumab) — known as Actemra in the U.S. — for treating adults hospitalized with severe COVID-19.
The drug, recommended for patients who require corticosteroids treatment and supplemental oxygen, works by inhibiting the body’s inflammatory reaction to COVID-19, called a cytokine storm.
The EMA’s human medicines committee assessed data from 4,116 hospitalized adults showing that patients given RoActemra plus standard of care had a reduced risk of death vs. those given standard of care alone.
In July, the World Health Organization (WHO) signed off on administering the drug plus corticosteroids for treating severe COVID-19.
Upcoming Events
-
21Mar
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr